drugset / Trial / NCT04260217
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.
Timeline
- Start
- 2021-05-30
- Primary completion
- 2024-02-05
- Completion
- 2025-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | 400 mg | Oral |
| Subject | APG-2575 | Small molecule | 600 mg | Oral |
| Subject | APG-2575 | Small molecule | 800 mg | Oral |